Skip to main content
Erschienen in: Die Chirurgie 4/2008

01.04.2008 | Leitthema

Antibiotika- und Pilztherapie bei intraabdominellen Infektionen

verfasst von: Prof. Dr. P. Kujath, M. Hoffmann, A. Rodloff

Erschienen in: Die Chirurgie | Ausgabe 4/2008

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die antimikrobielle Chemotherapie ist essenzieller Bestandteil in der Behandlung intraabdomineller Infektionen. Die initiale Antibiotikatherapie sollte nach Sicherung der Diagnose frühzeitig erfolgen. Die Auswahl des Antibiotikums muss sich am zu erwartenden Erregerspektrum im Sinne einer kalkulierten Therapie orientieren. Aufgrund der vorliegenden klinischen Studien ist eine generelle Empfehlung für ein bestimmtes Antibiotikum bzw. einer Substanzgruppe nicht möglich, da methodisch immer auf „Nichtunterlegenheit“ zum Vergleichsantibiotikum geprüft wurde. Auf der Basis einer Vielzahl von Studien haben die Fachgesellschaften Empfehlungen erarbeitet.
Die antibiotische Therapie der postoperativen Peritonitis sollte die besondere Risikokonstellation des Patienten wie antibiotische Vorbehandlung, das Auftreten multiresistenter Problemkeime und der hospitalen Epidemiologie Rechnung tragen. Das Auftreten peritonealer Mykosen ist selten. Die Therapie sollte nach mikrobiologischer Testung erfolgen.
Literatur
1.
Zurück zum Zitat Allo MD, Bennion RS, Kathir K et al. (1999) Ticarcillin/clavulanate versus imipenem/cilistatin for the treatment of infections associated with gangrenous and perforated appendicitis. Am Surg 65: 99–104PubMed Allo MD, Bennion RS, Kathir K et al. (1999) Ticarcillin/clavulanate versus imipenem/cilistatin for the treatment of infections associated with gangrenous and perforated appendicitis. Am Surg 65: 99–104PubMed
2.
Zurück zum Zitat Andäker L, Höjer H, Kihlström E et al. (1987) Stratified duration of prophylactic antimicrobial treatment in emergency abdominal surgery. Metronidazole-fosfomycin vs. metronidazole-gentamicin in 381 patients. Acta Chir Scand 153: 185–192PubMed Andäker L, Höjer H, Kihlström E et al. (1987) Stratified duration of prophylactic antimicrobial treatment in emergency abdominal surgery. Metronidazole-fosfomycin vs. metronidazole-gentamicin in 381 patients. Acta Chir Scand 153: 185–192PubMed
3.
Zurück zum Zitat Angeras MH, Darle N, Hamnström K et al. (1996) A comparison of imipenem/cilastatin with the combination of cefuroxime and metronidazole in the treatment of intra-abdominal infections. Scand J Infect Dis 28: 513–518PubMedCrossRef Angeras MH, Darle N, Hamnström K et al. (1996) A comparison of imipenem/cilastatin with the combination of cefuroxime and metronidazole in the treatment of intra-abdominal infections. Scand J Infect Dis 28: 513–518PubMedCrossRef
4.
Zurück zum Zitat Babinchak T, Ellis-Grosse E, Dartois N et al. (2005) The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis [Suppl 5] 41: S354–S367 Babinchak T, Ellis-Grosse E, Dartois N et al. (2005) The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis [Suppl 5] 41: S354–S367
5.
Zurück zum Zitat Barie PS, Vogel SB, Dellinger EP et al. for the Cefepime Intra-abdominal Infection Study Group (1997) A randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenem-cilastatin in the treatment of complicated intra-abdominal infections. Arch Surg 132: 1294–1302PubMed Barie PS, Vogel SB, Dellinger EP et al. for the Cefepime Intra-abdominal Infection Study Group (1997) A randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenem-cilastatin in the treatment of complicated intra-abdominal infections. Arch Surg 132: 1294–1302PubMed
6.
Zurück zum Zitat Blot SI, Vandewoude KH, De Waele JJ (2007) Candida peritonitis. Curr Opin Crit Care 13: 195–199PubMedCrossRef Blot SI, Vandewoude KH, De Waele JJ (2007) Candida peritonitis. Curr Opin Crit Care 13: 195–199PubMedCrossRef
7.
Zurück zum Zitat Bozorgzadeh A, Pizzi WF, Barie PS et al. (1999) The duration of antibiotic administration in penetrating abdominal trauma. Am J Surg 177: 125–131PubMedCrossRef Bozorgzadeh A, Pizzi WF, Barie PS et al. (1999) The duration of antibiotic administration in penetrating abdominal trauma. Am J Surg 177: 125–131PubMedCrossRef
8.
Zurück zum Zitat Brismar B, Malmborg AS, Tunevall G et al. (1995) Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections. J Antimicrob Chemother 35: 139–148PubMedCrossRef Brismar B, Malmborg AS, Tunevall G et al. (1995) Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections. J Antimicrob Chemother 35: 139–148PubMedCrossRef
9.
Zurück zum Zitat Burnett RJ, Haverstock DC, Dellinger EP et al. (1995) Definition of the role of enterococcus in intraabdominal infection: analysis of a prospective randomized trial. Surgery 118: 716–723PubMedCrossRef Burnett RJ, Haverstock DC, Dellinger EP et al. (1995) Definition of the role of enterococcus in intraabdominal infection: analysis of a prospective randomized trial. Surgery 118: 716–723PubMedCrossRef
10.
Zurück zum Zitat Calandra T, Bille J, Schneider R et al. (1989) Clinical significance of Candida isolated from peritoneum in surgical patients. Lancet 2: 1437–1440PubMedCrossRef Calandra T, Bille J, Schneider R et al. (1989) Clinical significance of Candida isolated from peritoneum in surgical patients. Lancet 2: 1437–1440PubMedCrossRef
11.
Zurück zum Zitat Cohn SM, Lipsett PA, Buchman PG et al. (2000) Comparison of intravenous/oral ciprofloxacin plus metronidazole versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections. Ann Surg 232: 254–262PubMedCrossRef Cohn SM, Lipsett PA, Buchman PG et al. (2000) Comparison of intravenous/oral ciprofloxacin plus metronidazole versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections. Ann Surg 232: 254–262PubMedCrossRef
12.
Zurück zum Zitat Dougherty SH, Sirinek KR, Schauer PR et al. (1995) Ticarcillin/clavulanate compared with clindamycin/gentamicin (with or without ampicillin) for the treatment of intra-abdominal infections in pediatric and adult patients. Am Surg 61: 297–303PubMed Dougherty SH, Sirinek KR, Schauer PR et al. (1995) Ticarcillin/clavulanate compared with clindamycin/gentamicin (with or without ampicillin) for the treatment of intra-abdominal infections in pediatric and adult patients. Am Surg 61: 297–303PubMed
13.
Zurück zum Zitat Dupont H, Bourichon A, Paugam-Burtz C et al. (2003) Can yeast isolation in peritoneal fluid be predicted in intensive care unit patients with peritonitis? Crit Care Med 31: 752–757PubMedCrossRef Dupont H, Bourichon A, Paugam-Burtz C et al. (2003) Can yeast isolation in peritoneal fluid be predicted in intensive care unit patients with peritonitis? Crit Care Med 31: 752–757PubMedCrossRef
14.
Zurück zum Zitat Eagye KJ, Kuti JL, Nicolau DP (2007) Evaluating empiric treatment options for secondary peritonitis using pharmacodynamic profiling. Surg Infect 8: 215–226CrossRef Eagye KJ, Kuti JL, Nicolau DP (2007) Evaluating empiric treatment options for secondary peritonitis using pharmacodynamic profiling. Surg Infect 8: 215–226CrossRef
15.
Zurück zum Zitat Eklund AE, Nord CE (1993) A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study Group. J Antimicrob Chemother [Suppl A] 31: 79–85 Eklund AE, Nord CE (1993) A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study Group. J Antimicrob Chemother [Suppl A] 31: 79–85
16.
Zurück zum Zitat Evans HL, Raymond DP, Pelletier SJ et al. (2001) Tertiary peritonitis (recurrent diffuse or localized peritonitis) is not an independent predictor of mortality in surgical patients with intraabdominal infection. Surg Infect 2: 255–263CrossRef Evans HL, Raymond DP, Pelletier SJ et al. (2001) Tertiary peritonitis (recurrent diffuse or localized peritonitis) is not an independent predictor of mortality in surgical patients with intraabdominal infection. Surg Infect 2: 255–263CrossRef
17.
Zurück zum Zitat Fabian TC, Croce MA, Payne LW et al. (1992) Duration of antibiotic therapy for penetrating abdominal trauma: a prospective trial. Surgery 112: 788–795PubMed Fabian TC, Croce MA, Payne LW et al. (1992) Duration of antibiotic therapy for penetrating abdominal trauma: a prospective trial. Surgery 112: 788–795PubMed
18.
Zurück zum Zitat Hopkins JA, Wilson SE, Bobey DG (1994) Adjunctive antimicrobial therapy for complicated appendicitis: bacterial overkill by combination therapy. World J Surg 18: 933–938PubMedCrossRef Hopkins JA, Wilson SE, Bobey DG (1994) Adjunctive antimicrobial therapy for complicated appendicitis: bacterial overkill by combination therapy. World J Surg 18: 933–938PubMedCrossRef
19.
Zurück zum Zitat Huizinga WK, Warren BL, Baker LW et al. (1995) Antibiotic monotherapy with meropenem in the surgical management of intra-abdominal infections. J Antimicrob Chemother [Suppl A] 36: 179–189 Huizinga WK, Warren BL, Baker LW et al. (1995) Antibiotic monotherapy with meropenem in the surgical management of intra-abdominal infections. J Antimicrob Chemother [Suppl A] 36: 179–189
20.
Zurück zum Zitat Jaccard C, Troillet N, Harbarth S et al. (1998) Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother 42: 2966–2972PubMed Jaccard C, Troillet N, Harbarth S et al. (1998) Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother 42: 2966–2972PubMed
21.
Zurück zum Zitat Kirton OC, O’Neill PA, Kestner M et al. (2000) Perioperative antibiotic use in high-risk penetrating hollow viscus injury: a prospective randomized, doubleblind, placebo-control trial of 24 hours versus 5 days. J Trauma 49: 822–832PubMedCrossRef Kirton OC, O’Neill PA, Kestner M et al. (2000) Perioperative antibiotic use in high-risk penetrating hollow viscus injury: a prospective randomized, doubleblind, placebo-control trial of 24 hours versus 5 days. J Trauma 49: 822–832PubMedCrossRef
22.
Zurück zum Zitat Krepel CJ, Gohr C, Edmiston CE, Condon RE (1995) Surgical sepsis: constancy of antibiotic susceptibility of causativ organismns. Surgery 117: 505–509PubMedCrossRef Krepel CJ, Gohr C, Edmiston CE, Condon RE (1995) Surgical sepsis: constancy of antibiotic susceptibility of causativ organismns. Surgery 117: 505–509PubMedCrossRef
23.
Zurück zum Zitat Kujath P (2002) Peritonitis. Uni-Med, Bremen Kujath P (2002) Peritonitis. Uni-Med, Bremen
24.
Zurück zum Zitat Lau WK, Mercer D, Itani KM et al. (2006) Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection. Antimicrob Agents Chemother 50: 3556–3561PubMedCrossRef Lau WK, Mercer D, Itani KM et al. (2006) Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection. Antimicrob Agents Chemother 50: 3556–3561PubMedCrossRef
25.
Zurück zum Zitat Lennard ES, Minshew BH, Dellinger EP, Wertz M (1980) Leukocytosis at termination of antibiotic therapy: its importance for intra-abdominal sepsis. Arch Surg 115: 918–921PubMed Lennard ES, Minshew BH, Dellinger EP, Wertz M (1980) Leukocytosis at termination of antibiotic therapy: its importance for intra-abdominal sepsis. Arch Surg 115: 918–921PubMed
26.
Zurück zum Zitat Lennard ES, Dellinger EP, Wertz MJ, Minshew BH (1982) Implications of leukocytosis and fever at conclusion of antibiotic therapy for intraabdominal sepsis. Ann Surg 195: 19–24PubMedCrossRef Lennard ES, Dellinger EP, Wertz MJ, Minshew BH (1982) Implications of leukocytosis and fever at conclusion of antibiotic therapy for intraabdominal sepsis. Ann Surg 195: 19–24PubMedCrossRef
27.
Zurück zum Zitat Luke M, Iversen S, Sondergaard J et al. (1991) Ceftriaxone/metronidazole is more effective than ampicillin/netilmicin/metronidazole in the treatment of bacterial peritonitis. Eur J Surg 157: 397–401PubMed Luke M, Iversen S, Sondergaard J et al. (1991) Ceftriaxone/metronidazole is more effective than ampicillin/netilmicin/metronidazole in the treatment of bacterial peritonitis. Eur J Surg 157: 397–401PubMed
28.
Zurück zum Zitat Marangoni M, Song J, Herrington J et al. (2006) Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections. Ann Surg 244(2): 204–211CrossRef Marangoni M, Song J, Herrington J et al. (2006) Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections. Ann Surg 244(2): 204–211CrossRef
29.
Zurück zum Zitat Marshall JC, Christou NV, Horn R, Meakins JL (1988) The microbiology of multiple organ failure. Arch Surg 123: 309–315PubMed Marshall JC, Christou NV, Horn R, Meakins JL (1988) The microbiology of multiple organ failure. Arch Surg 123: 309–315PubMed
30.
Zurück zum Zitat Mazuski JE, Sawyer RG, Nathens AB et al. (2002) The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: evidence for the recommendations. Surg Infect 3: 175–233CrossRef Mazuski JE, Sawyer RG, Nathens AB et al. (2002) The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: evidence for the recommendations. Surg Infect 3: 175–233CrossRef
31.
Zurück zum Zitat McGowan JE Jr, Gerding DN (1996) Does antibiotic restriction prevent resistance? New Horiz 4: 370–376PubMed McGowan JE Jr, Gerding DN (1996) Does antibiotic restriction prevent resistance? New Horiz 4: 370–376PubMed
32.
Zurück zum Zitat Montravers P, Gauzit R, Muller C et al. (1996) Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin Infect Dis 23: 486–494PubMed Montravers P, Gauzit R, Muller C et al. (1996) Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin Infect Dis 23: 486–494PubMed
33.
Zurück zum Zitat Montravers P, Dupont H, Gauzit R et al. (2006) Candida as a risk factor for mortality in peritonitis. Crit Care Med 34: 646–652PubMedCrossRef Montravers P, Dupont H, Gauzit R et al. (2006) Candida as a risk factor for mortality in peritonitis. Crit Care Med 34: 646–652PubMedCrossRef
34.
Zurück zum Zitat Nathens AB, Rotstein OD, Marshall JC (1998) Tertiary peritonitis: clinical features of a complex nosocomial infection. World J Surg 22: 158–163PubMedCrossRef Nathens AB, Rotstein OD, Marshall JC (1998) Tertiary peritonitis: clinical features of a complex nosocomial infection. World J Surg 22: 158–163PubMedCrossRef
35.
Zurück zum Zitat Nathens AB, Cook CH, Machiedo G et al. (2006) Defining the research agenda for surgical infection: a consensus of experts using the Delphi approach. Surg Infect 7: 101–110CrossRef Nathens AB, Cook CH, Machiedo G et al. (2006) Defining the research agenda for surgical infection: a consensus of experts using the Delphi approach. Surg Infect 7: 101–110CrossRef
36.
Zurück zum Zitat Nguyen MH, Yu VL, Morris AJ et al. (2000) Antimicrobial resistance and clinical outcome of Bacteroides bacteremia: findings of a multicenter prospective observational trial. Clin Infect Dis 30: 870–876PubMedCrossRef Nguyen MH, Yu VL, Morris AJ et al. (2000) Antimicrobial resistance and clinical outcome of Bacteroides bacteremia: findings of a multicenter prospective observational trial. Clin Infect Dis 30: 870–876PubMedCrossRef
37.
Zurück zum Zitat Ohlin B, Cederberg A, Forssell H et al. (1999) Piperacillin/tazobactam compared with cefuroxime/metronidazole in the treatment of intra-abdominal infections. Eur J Surg 165: 875–884PubMedCrossRef Ohlin B, Cederberg A, Forssell H et al. (1999) Piperacillin/tazobactam compared with cefuroxime/metronidazole in the treatment of intra-abdominal infections. Eur J Surg 165: 875–884PubMedCrossRef
38.
Zurück zum Zitat Paul M, Silbiger I, Grozinsky S et al. (2006) Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 1: CD003344PubMed Paul M, Silbiger I, Grozinsky S et al. (2006) Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 1: CD003344PubMed
39.
Zurück zum Zitat Peoples JB (1986) Candida and perforated peptic ulcers. Surgery 100: 758–764PubMed Peoples JB (1986) Candida and perforated peptic ulcers. Surgery 100: 758–764PubMed
40.
41.
42.
Zurück zum Zitat Roehrborn A, Thomas L, Potreck O et al. (2001) The microbiology of postoperative peritonitis. Clin Infect Dis 33: 1513–1519PubMedCrossRef Roehrborn A, Thomas L, Potreck O et al. (2001) The microbiology of postoperative peritonitis. Clin Infect Dis 33: 1513–1519PubMedCrossRef
43.
Zurück zum Zitat Rossi F, Baquero F, Hsueh PR et al. (2006) In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). J Antimicrob Chemother 58: 205–210PubMedCrossRef Rossi F, Baquero F, Hsueh PR et al. (2006) In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). J Antimicrob Chemother 58: 205–210PubMedCrossRef
44.
Zurück zum Zitat Rotstein OD, Meakins JL (1990) Diagnostic and therapeutic challenges of intraabdominal infections. World J Surg 14: 159–166PubMedCrossRef Rotstein OD, Meakins JL (1990) Diagnostic and therapeutic challenges of intraabdominal infections. World J Surg 14: 159–166PubMedCrossRef
45.
Zurück zum Zitat Schein M, Assalia A, Bachus H (1994) Minimal antibiotic therapy after emergency abdominal surgery: a prospective study. Br J Surg 81: 989–991PubMedCrossRef Schein M, Assalia A, Bachus H (1994) Minimal antibiotic therapy after emergency abdominal surgery: a prospective study. Br J Surg 81: 989–991PubMedCrossRef
46.
Zurück zum Zitat Seguin P, Laviolle B, Chanavaz C et al. (2006) Factors associated with multidrugresistant bacteria in secondary peritonitis: impact on antibiotic therapy. Clin Microbiol Infect 12: 980–985PubMedCrossRef Seguin P, Laviolle B, Chanavaz C et al. (2006) Factors associated with multidrugresistant bacteria in secondary peritonitis: impact on antibiotic therapy. Clin Microbiol Infect 12: 980–985PubMedCrossRef
47.
Zurück zum Zitat Shlaes DM, Gerding DN, John JF Jr et al. (1997) Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 25: 584–599PubMedCrossRef Shlaes DM, Gerding DN, John JF Jr et al. (1997) Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 25: 584–599PubMedCrossRef
48.
Zurück zum Zitat Sitges-Serra A, Lopez M, Girvent M et al. (2002) Postoperative enterococcal infection after treatment of complicated intra-abdominal sepsis. Br J Surg 89: 361–367PubMedCrossRef Sitges-Serra A, Lopez M, Girvent M et al. (2002) Postoperative enterococcal infection after treatment of complicated intra-abdominal sepsis. Br J Surg 89: 361–367PubMedCrossRef
49.
Zurück zum Zitat Snydman DR, Cuchural GJ Jr, McDermott L, Gill M (1992) Correlation of various in vitro testing methods with clinical outcomes in patients with Bacteroides fragilis group infections treated with cefoxitin: a retrospective analysis. Antimicrob Agents Chemother 36: 540–544PubMed Snydman DR, Cuchural GJ Jr, McDermott L, Gill M (1992) Correlation of various in vitro testing methods with clinical outcomes in patients with Bacteroides fragilis group infections treated with cefoxitin: a retrospective analysis. Antimicrob Agents Chemother 36: 540–544PubMed
50.
Zurück zum Zitat Solomkin JS, Flohr AB, Quie PG, Simmons RL (1980) The role of Candida in intraperitoneal infections. Surgery 88: 524–530PubMed Solomkin JS, Flohr AB, Quie PG, Simmons RL (1980) The role of Candida in intraperitoneal infections. Surgery 88: 524–530PubMed
51.
Zurück zum Zitat Solomkin JS, Mazuski JE, Baron EJ et al. (2003) Guidelines for the selection of antiinfective agents for complicated intra-abdominal infections. Clin Infect Dis 37: 997–1005PubMedCrossRef Solomkin JS, Mazuski JE, Baron EJ et al. (2003) Guidelines for the selection of antiinfective agents for complicated intra-abdominal infections. Clin Infect Dis 37: 997–1005PubMedCrossRef
52.
Zurück zum Zitat Solomkin JS, Reinhart HH, Dellinger EP et al. (1996) Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group. Ann Surg 223: 303–315PubMedCrossRef Solomkin JS, Reinhart HH, Dellinger EP et al. (1996) Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group. Ann Surg 223: 303–315PubMedCrossRef
53.
Zurück zum Zitat Solomkin JS, Yellin AE, Rotstein OD et al. (2003) Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial. Ann Surg 237: 235–245PubMedCrossRef Solomkin JS, Yellin AE, Rotstein OD et al. (2003) Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial. Ann Surg 237: 235–245PubMedCrossRef
54.
Zurück zum Zitat Trede M, Linder MM, Welsch G (1980) Die Indikation zur Relaparotomie bei postoperativer Peritonitis. Langenbecks Arch Chir 352: 295CrossRef Trede M, Linder MM, Welsch G (1980) Die Indikation zur Relaparotomie bei postoperativer Peritonitis. Langenbecks Arch Chir 352: 295CrossRef
55.
Zurück zum Zitat Vogel F, Bodmann KF und die Expertenkommision der Paul-Ehrlich-Gesellschaft (2004) Empfehlungen zur kalkulierten parenteralen Initialtherapie bakterieller Erkrankungen bei Erwachsenen. Chemother J 13: 46–105 Vogel F, Bodmann KF und die Expertenkommision der Paul-Ehrlich-Gesellschaft (2004) Empfehlungen zur kalkulierten parenteralen Initialtherapie bakterieller Erkrankungen bei Erwachsenen. Chemother J 13: 46–105
56.
Zurück zum Zitat Walker AP, Nichols RL, Wilson RF et al. (1993) Efficacy of a beta-lactamase inhibitor combination for serious intraabdominal infections. Ann Surg 217: 115–121PubMedCrossRef Walker AP, Nichols RL, Wilson RF et al. (1993) Efficacy of a beta-lactamase inhibitor combination for serious intraabdominal infections. Ann Surg 217: 115–121PubMedCrossRef
57.
Zurück zum Zitat Wittmann DH, Schein M (1996) Let us shorten antibiotic prophylaxis and therapy in surgery. Am J Surg 172: 26S–32SPubMedCrossRef Wittmann DH, Schein M (1996) Let us shorten antibiotic prophylaxis and therapy in surgery. Am J Surg 172: 26S–32SPubMedCrossRef
58.
Zurück zum Zitat Wong PF, Gilliam AD, Kumar S et al. (2005) Antibiotic regimens for secondary peritonitis of gastrointestinal origin in adults. Cochrane Database Syst Rev 2: CD004539PubMed Wong PF, Gilliam AD, Kumar S et al. (2005) Antibiotic regimens for secondary peritonitis of gastrointestinal origin in adults. Cochrane Database Syst Rev 2: CD004539PubMed
59.
Zurück zum Zitat Yellin AE, Heseltine PN, Berne TV et al. (1985) The role of Pseudomonas species in patients treated with ampicillin and sulbactam for gangrenous and perforated appendicitis. Surg Gynecol Obstet 161: 303–307PubMed Yellin AE, Heseltine PN, Berne TV et al. (1985) The role of Pseudomonas species in patients treated with ampicillin and sulbactam for gangrenous and perforated appendicitis. Surg Gynecol Obstet 161: 303–307PubMed
60.
Zurück zum Zitat Basoli A, Meli EZ, Mazzocchi P et al. (1997) Imipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patients with intra-abdominal infections: results of a prospective, randomized, multicentre trial. Scand J Infect Dis 29(5): 503–508PubMedCrossRef Basoli A, Meli EZ, Mazzocchi P et al. (1997) Imipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patients with intra-abdominal infections: results of a prospective, randomized, multicentre trial. Scand J Infect Dis 29(5): 503–508PubMedCrossRef
61.
Zurück zum Zitat Condon RE, Walker AP, Sirinek KR et al. (1995) Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: results of a prospective, randomized, double-blind clinical trial. Clin Infect Dis 21:544–550PubMed Condon RE, Walker AP, Sirinek KR et al. (1995) Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: results of a prospective, randomized, double-blind clinical trial. Clin Infect Dis 21:544–550PubMed
62.
Zurück zum Zitat Namias N, Solomkin JS, Jensen EH et al. (2007) Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adults. Surg Infect 8(1): 15–28CrossRef Namias N, Solomkin JS, Jensen EH et al. (2007) Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adults. Surg Infect 8(1): 15–28CrossRef
63.
Zurück zum Zitat Poenaru D, de Santis M, Christou NV (1990) Imipenem versus tobramycin – antianaerobe antibiotic therapy in intra-abdominal infections. Can J Surg 33: 415–422PubMed Poenaru D, de Santis M, Christou NV (1990) Imipenem versus tobramycin – antianaerobe antibiotic therapy in intra-abdominal infections. Can J Surg 33: 415–422PubMed
64.
Zurück zum Zitat Mehtar S, Dewar EP, Leaper DJ et al. (1997) A multi-centre study to compare meropenem and cefotaxime and metronidazole in the treatment of hospitalized patients with serious infection. J Antimicrob Chemother 39: 631–638PubMedCrossRef Mehtar S, Dewar EP, Leaper DJ et al. (1997) A multi-centre study to compare meropenem and cefotaxime and metronidazole in the treatment of hospitalized patients with serious infection. J Antimicrob Chemother 39: 631–638PubMedCrossRef
65.
Zurück zum Zitat Kumar A, Roberts D, Wood KE et al. (2006) Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34: 1589–1596PubMedCrossRef Kumar A, Roberts D, Wood KE et al. (2006) Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34: 1589–1596PubMedCrossRef
66.
Zurück zum Zitat Niederman MS (2006) Use of broad-spectrum antimicrobials for the treatment of pneumonia in seriously ill patients: maximizing clinical outcomes and minimizing selection of resistant organisms. Clin Infect Dis 42 [Suppl 2]: 72–81 Niederman MS (2006) Use of broad-spectrum antimicrobials for the treatment of pneumonia in seriously ill patients: maximizing clinical outcomes and minimizing selection of resistant organisms. Clin Infect Dis 42 [Suppl 2]: 72–81
Metadaten
Titel
Antibiotika- und Pilztherapie bei intraabdominellen Infektionen
verfasst von
Prof. Dr. P. Kujath
M. Hoffmann
A. Rodloff
Publikationsdatum
01.04.2008
Verlag
Springer-Verlag
Erschienen in
Die Chirurgie / Ausgabe 4/2008
Print ISSN: 2731-6971
Elektronische ISSN: 2731-698X
DOI
https://doi.org/10.1007/s00104-008-1484-z

Weitere Artikel der Ausgabe 4/2008

Die Chirurgie 4/2008 Zur Ausgabe

Nachrufe

In Memoriam

Einführung zum Thema

Behandlung der Peritonitis

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.